Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 3.65B | 3.54B | 3.09B | 3.38B | 2.68B |
Gross Profit | 1.74B | 1.71B | 1.42B | 1.42B | 1.20B |
EBITDA | 893.87M | 913.55M | 794.03M | 795.27M | 787.26M |
Net Income | 460.80M | 530.43M | 448.06M | 468.13M | 557.24M |
Balance Sheet | |||||
Total Assets | 6.85B | 6.50B | 5.48B | 5.01B | 5.01B |
Cash, Cash Equivalents and Short-Term Investments | 1.66B | 1.08B | 960.11M | 1.57B | 1.74B |
Total Debt | 1.32B | 1.27B | 568.45M | 233.87M | 123.93M |
Total Liabilities | 2.80B | 2.54B | 1.70B | 1.33B | 1.36B |
Stockholders Equity | 4.03B | 3.97B | 3.78B | 3.67B | 3.65B |
Cash Flow | |||||
Free Cash Flow | 403.85M | 966.59M | 273.38M | 282.47M | 511.94M |
Operating Cash Flow | 527.30M | 1.10B | 653.69M | 598.55M | 773.29M |
Investing Cash Flow | -306.29M | -1.21B | -1.18B | -280.05M | -190.78M |
Financing Cash Flow | -471.60M | 227.99M | -90.43M | -482.92M | -590.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | HK$17.43B | 11.14 | 13.55% | 4.17% | 13.03% | 22.23% | |
75 Outperform | $53.13B | 13.58 | 22.98% | 5.71% | 10.50% | 10.34% | |
74 Outperform | €4.42B | 9.67 | 10.67% | 9.49% | 3.23% | -21.82% | |
73 Outperform | HK$1.02B | 31.73 | 2.21% | 1.19% | -14.05% | 20.05% | |
71 Outperform | HK$844.47M | 6.13 | 6.38% | 4.10% | 7.08% | 190.74% | |
69 Neutral | $2.91B | 12.99 | 2.27% | 4.24% | -4.65% | ― | |
56 Neutral | HK$25.46B | 5.06 | -2.69% | 5.60% | -0.43% | -53.15% |
China Lilang Ltd. has announced its unaudited consolidated results for the first half of 2025, revealing its financial performance and operational outcomes. The interim results, which comply with the Hong Kong Stock Exchange’s listing requirements, provide stakeholders with insights into the company’s current market positioning and potential future developments.
The most recent analyst rating on (HK:1234) stock is a Buy with a HK$4.85 price target. To see the full list of analyst forecasts on China Lilang Ltd. stock, see the HK:1234 Stock Forecast page.
China Lilang Limited has announced a board meeting scheduled for August 12, 2025, to approve the unaudited consolidated interim results for the first half of the year and to consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1234) stock is a Buy with a HK$4.96 price target. To see the full list of analyst forecasts on China Lilang Ltd. stock, see the HK:1234 Stock Forecast page.
China Lilang Ltd. reported mid-to-high-single-digit growth in retail sales for its LILANZ products in both the second quarter and the first half of 2025 compared to the same periods in 2024. This operational update, based on preliminary unaudited data, suggests a positive trend in the company’s retail performance, although it does not fully represent the group’s overall financial results. Stakeholders are advised to exercise caution as the information may be subject to change.
The most recent analyst rating on (HK:1234) stock is a Buy with a HK$4.96 price target. To see the full list of analyst forecasts on China Lilang Ltd. stock, see the HK:1234 Stock Forecast page.
China Lilang Limited has announced the appointment of Prof. Liao Jianwen and Prof. Jiang Zhan as independent non-executive directors. Both professors have confirmed their independence according to the Listing Rules, with no financial or other interests in the company’s business, ensuring their impartiality in governance.
The most recent analyst rating on (HK:1234) stock is a Buy with a HK$4.85 price target. To see the full list of analyst forecasts on China Lilang Ltd. stock, see the HK:1234 Stock Forecast page.